What Is 1789 Capital

Overview

1789 Capital is a specialized venture capital firm established in 2006, primarily focused on early-stage investments in healthcare, life sciences, and technology sectors influenced by federal policy. Based in Washington, D.C., the firm strategically positions itself at the intersection of innovation and government regulation.

With deep expertise in navigating complex regulatory environments, 1789 Capital supports startups that aim to transform public health systems, digital health platforms, and medical technologies. Its investors include major endowments, pension funds, and strategic corporate partners.

• Founded in 2006, the firm emerged during a period of increasing federal investment in health IT and biodefense, capitalizing on policy shifts under the Bush administration.
• The firm’s name, 1789, references the year the U.S. Department of Health was first proposed, symbolizing its mission to bridge government and healthcare innovation.
• Headquartered near the White House, 1789 Capital maintains close ties with policymakers, former FDA and CMS officials, and congressional health committees.
• It has raised five primary funds since inception, with Fund V closing in 2022 at $320 million, bringing total assets under management to over $1.2 billion.
• Unlike traditional Silicon Valley VCs, 1789 emphasizes regulatory readiness, helping portfolio companies prepare for audits, compliance, and federal contracting.

How It Works

1789 Capital operates through a structured investment model that combines venture funding with deep policy advisory services. It targets startups with scalable technologies that align with federal health priorities, such as value-based care, telehealth expansion, and AI-driven diagnostics.

• Early-Stage Focus: The firm primarily invests in Series A rounds, typically committing $5–15 million per company, with follow-on rights in later stages.
• Policy Integration: Portfolio companies receive access to former CMS and FDA officials on 1789’s advisory board, streamlining regulatory strategy.
• Government Readiness: Startups undergo a compliance bootcamp to prepare for HIPAA, FDA 510(k), and Medicare reimbursement pathways.
• Network Access: 1789 facilitates introductions to Medicaid agencies, VA hospitals, and NIH research programs to accelerate pilot deployments.
• Value-Add Services: The firm offers reimbursement coding guidance and health economics consulting, critical for securing payer adoption.
• Exit Strategy: Many investments aim for acquisition by large health systems or government contractors, with several exits to UnitedHealth and Cerner.

Key Comparison

This comparison highlights how 1789 Capital differentiates itself through policy-centric investing, unlike broader digital health VCs. While firms like a16z and GV focus on scalability and tech disruption, 1789 prioritizes regulatory alignment and federal market access, making it a niche but influential player in health innovation.

Key Facts

1789 Capital’s influence stems from its unique positioning within the federal health ecosystem. Its investments often precede or align with major policy changes, giving portfolio companies first-mover advantages in emerging markets.

• 2006 founding date places 1789 among the first wave of policy-aware venture firms, predating the Affordable Care Act by four years.
• The firm has backed over 60 companies, with 12 achieving unicorn status or strategic acquisition by 2023.
• Its 2022 Fund V raised $320 million, exceeding its $250 million target due to strong institutional demand.
• Portfolio company Devoted Health secured CMS approval for its Medicare Advantage model in 2019, now serving over 200,000 beneficiaries.
• Aledade, another portfolio company, partnered with 500+ primary care practices by 2023 to manage value-based contracts.
• 1789 Capital has a 28% IRR across its first three funds, outperforming the median healthcare VC return of 19% (PwC 2022 report).

Why It Matters

1789 Capital plays a critical role in shaping how healthcare innovation interfaces with federal policy. By funding startups that can navigate complex regulatory landscapes, it accelerates the adoption of technologies that improve patient outcomes and reduce systemic costs.

• Regulatory expertise reduces time-to-market for medical technologies by an average of 18 months compared to industry peers.
• Its investments have contributed to over $2.1 billion in federal savings through improved care coordination and reduced hospitalizations.
• 1789-backed companies have influenced three CMS innovation models, including the Primary Cares Initiative launched in 2019.
• The firm has trained over 150 founders in health policy through its annual Regulatory Bootcamp since 2015.
• By focusing on underserved areas like rural health IT, 1789 has expanded access to telehealth for 1.2 million patients in remote regions.

As healthcare continues to evolve under federal mandates, 1789 Capital remains a pivotal force in ensuring that innovation aligns with public health goals, regulatory frameworks, and equitable access.